Rhythm Pharmaceuticals Inc. announced that it has entered into Product Listing Agreements in the provinces of Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia, and with the Federal Non-Insured Health Benefits (NIHB) Program for the public reimbursement of IMCIVREE (setmelanotide). The agreements cover weight management in eligible adult and pediatric patients aged 6 years and older with clinically or genetically confirmed Bardet-Biedl syndrome (BBS) and obesity. IMCIVREE was approved by Health Canada in May 2023 and was recently added to the common list of new drugs for rare diseases under the Government of Canada's National Strategy for Drugs for Rare Diseases.